Deploi.no tilbyr virtuelle servere, enkelt og greit. Vi legger vi stor vekt på å øke servernes ytelse, samtidig som vi presser prisene nedover. Vi opplever etablerte aktører i bransjen som tunge og dyre, og ønsker å gjøre noe med dette.Vi kan skilte med en rekke forhåndsinstallerte operativsystemer og applikasjoner, og våre produkter skal være enkle å administrere.

Agri-e produces Electricity, heat, Hydrogen, and concentrated CO2 from biogas. Increase biogas value, and increase Food production by use of green concentrated CO2 in a greenhouse, Al has done this in a sustainable way by use of biogas produced from different biological waste streams considered a problem today. Decentralized and scalable energy production to relieve peak stress in el-grid. We are contributing to solving our generation's biggest issue: Producing food and energy in a sustainable green way

Miksapix Interactive is an indie app development company that produces interactive storytelling apps for kids with Sami folk tales and legends. Miksapix Interactive is a production company that specializes in developing apps and games. The company also sells digital products and services in a wide range and focuses on the utilization of new technology and creating good user experiences in the borderland between art, technology, and design.

TradingFoé is a Norwegian marketplace platform which connects Norwegian and Asian businesses. We are providing the best sales methodologies and international portal that help company approach right and on-time partners, increase sales and open new markets. Building a fully integrate platform across the country border, from the product in warehouse of a seller, to the inventory of the buyer, federated in trustful system, right and in-time partners, transparent smart contracts. This is Vikr™. TradingFoe platform is using matchotify algorithms, the most powerful and simple solution called Vikr™.

24Nettbutikk is one of the leading e-commerce platforms in the Norwegian market. More than 1200 small and medium businesses currently use the platform to sell their products through digital channels. 24Nettbutikk focuses on developing strong partnerships and technical integrations with leading providers of services such as logistics, payments and marketing to offer a complete solution for our merchants at a competitive cost. We have a strong focus on our customer's success and work hard every day to ensure that customers experience a short time to value and continuous growth in sales volume.

Nutcracker Solutions owns the product StadiaPitch by Bosch Rexroth and have licensed it to Bosch Rexroth until 2038.  The product is sold worldwide by the Bosch Corporation, and Nutcracker is a part of Bosch`s International StadiaPItch sales team. The goal is to reach 4 sales a year. Bosch pays Nutcracker a license fee between €1M - €1.5M per sale. 90% of the fee is due 5 months after Bosch has signed the contract with the stadium. Nutcracker has a flat predictable annual operating cost of €0.4M, regardless of how many StadiaPitch Sales Bosch Rexroth has in that year.  StadiaPitch entered the commercial phase in 2018 and has received an overwhelming market response. StadiaPitch is today included in the architectural drawings on three stadium projects, and Bosch has solid interest from several of the largest clubs in the world. StadiaPitch has received interest from architects, stadiums, and other stakeholders from 25 countries in the last 12 months.  Nutcracker is a dividend stock and the company is priced at 40 MNOK – pre-money. Nutcracker runs a Private Placement of 1OMNOK through a share issue that will equal to 20% of the new total number of shares. This funding will be spent on IPR, activities that enhance Bosch`s global sales work, and operating costs until we get income from the first Bosch contract. We pay a preference dividend equivalent to 50% of the investment for new investors. We have a commitment of 9 MNOK and we close the placement when we reach after the NXT 2019 events.

Moderne Media ble startet med et ønske om å formidle gode historier. Det er fortsatt kjerneverdien i alt vi gjør. Med podkast, TV, film, reklame og sosiale medier, har vi flere muligheter enn noen gang til å produsere og dele gode historier.Folkene du møter i Moderne Media jobber med det de synes er morsomst, og det de er flinkest til. Vi har oppdaget at de to tingene har en sammenheng. Derfor prøver vi å rendyrke personligheter og individer.

Otivio’s main product, FlowOx™, is addressing chronic wounds with focus on peripheral arterial disease (PAD), which is a serious condition leading to pain, chronic wounds and in many cases amputation and mortality. The patient population is very large and increasing. There are limited adequate treatment options offered to the patients aside from surgical interventions. FlowOx™ is a non-invasive product intended for home use. Long-term patient testing in more than 50 patients documents increased blood flow, reduced pain and wound healing. FlowOx™ is CE marked. In fourth quarter 2017 had its commercial break-through through sales of FlowOx to public customers.

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.

Preventing One Million Falls Before 2024 Dele Health Tech is redefining how the market conceptualizes and achieves fall prevention by offering a data fusion platform that functions as middleware between hardware and data stream partners. Our mission: To save lives through fall prevention, and prevent one million falls by 2024.

BRIK as is a company specialising in new web technology, pedagogy and professional dissemination of knowledge. The team has extensive experience in the dissemination of knowledge with new web technologies and video. Our investors and partners are Innovation Norway, the Norwegian Research Council and several customer partners. The budget for the initial development phase (2013 - ) has been 12 MNOK. Now we are looking for partners for the next stage, where we will commercialize and increase sales.

Konsulentselskapet Finova har et bredt spekter av tjenester innen rådgivning til bedriftseiere i SMB-segmentet. Vi bistår fra stiftelse gjennom vekst til salg av virksomheten.Vårt datterselskap Ontogeny Corporate Finance er spesialisert på relevante tjenester innen finansiering og transaksjoner. Verdiutvikling av selskap og aktivt eierskap.

Homeboxx is a convenient box for private homes or workplaces for the delivery of goods ordered from online stores regardless of the recipient's home or not. The Box is equipped with an electronic lock to keep the groceries safe and protected at all times. The box will have insulation material and may also have an active cooling or heating system to ensure different temperature zones, chilled and normally for temperature-sensitive goods like food. An app is included in the box to communicate with the end user, carrier, and the online store.

Vi forenkler hverdagen Rubic ble etablert i April 2014 med mål om å forenkle hverdagen for lag og foreninger i Norge. Vår ambisjon er å bli markedsleder i Norge for medlemsbaserte organisasjoner. Vi leverer ekspertise og systemer innenfor privat-, offentlig- og frivillig sektor. Drift smartere, mer tid Vi hjelper din forening med å drive profesjonelt og yte bedre service til deres medlemmer.

We believe in People! The understanding that culture is important has in recent years become a major focus area for many companies. Research says that managers want better information on how to better utilize the strengths of employees. The tools they have seen today are not adapted to the everyday lives of managers. Quick and easy overview of what matters for how to manage the organization tomorrow. Based on this, we started Xientia to give leaders better tools to describe how the organization really is. The analyzes should be easy to interpret and implement for all employees.